Dr. Jennifer Chan is clinical director of the Gastrointestinal Cancer Center and director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute in Boston.
April 13, 2025
Video
Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.
IV Complications and the Challenge of Being Heard
Save Meds, Save Lives: How to Donate Your Extra Cancer Medication
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Welireg Improves Quality-Adjusted Survival Time in Advanced RCC